ObsEva SA Shares Outstanding 2016-2021 | OBSV

ObsEva SA shares outstanding from 2016 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
ObsEva SA Annual Shares Outstanding
(Millions of Shares)
2020 50
2019 44
2018 40
2017 30
2016 3
2015 2
ObsEva SA Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 76
2021-03-31 69
2020-12-31 50
2020-09-30 50
2020-06-30 48
2020-03-31 46
2019-12-31 44
2019-09-30 44
2019-06-30 43
2019-03-31 43
2018-12-31 40
2018-09-30 43
2018-06-30 38
2018-03-31 36
2017-12-31 30
2017-09-30 29
2017-06-30 28
2017-03-31 27
2016-12-31 3
2016-09-30 21
2016-06-30 21
2016-03-31 21
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.187B $0.000B
ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29